GAUSH MEDITECH LTD |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14 HKD | -9.33% |
|
-18.78% | -62.70% |
| May. 30 | Gaush Meditech Ltd Declares Final Dividend for the Year Ended December 31, 2023 | CI |
| May. 29 | Gaush Meditech Gets China Nod for Intraocular Lenses for Cataract Patients | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 49% by 2026.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The company returns high margins, thereby supporting business profitability.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
- The company appears to be poorly valued given its net asset value.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -62.70% | 293M | - | ||
| -9.39% | 8.78B | B+ | ||
| +1.58% | 1.45B | D | ||
| -8.30% | 1.35B | B+ | ||
| -4.89% | 1.17B | - | ||
| -28.86% | 746M | - | - | |
| +1.67% | 462M | - | ||
| +1.47% | 432M | - | - | |
| -35.28% | 286M | - | - | |
| -0.08% | 215M | - | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 2407 Stock
- Ratings Gaush Meditech Ltd
